• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dosing forgiveness of oral PrEP for cisgender women remains uncertain.

作者信息

Moore Mia, Glidden David, Anderson Peter, Hendrix Craig, Dimitrov Dobromir

机构信息

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

School of Medicine, University of California, San Francisco, California, USA.

出版信息

J Int AIDS Soc. 2025 May;28(5):e26496. doi: 10.1002/jia2.26496.

DOI:10.1002/jia2.26496
PMID:40384398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12086362/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/12086362/ff0bc78f8b8c/JIA2-28-e26496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/12086362/ff0bc78f8b8c/JIA2-28-e26496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/12086362/ff0bc78f8b8c/JIA2-28-e26496-g001.jpg

相似文献

1
Dosing forgiveness of oral PrEP for cisgender women remains uncertain.对于顺性别女性口服暴露前预防药物（PrEP）的剂量豁免仍不确定。
J Int AIDS Soc. 2025 May;28(5):e26496. doi: 10.1002/jia2.26496.
2
Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.顺性别女性中恩曲他滨和富马酸替诺福韦二吡呋酯暴露前预防的依从性和 HIV 保护阈值：系统评价。
Curr HIV/AIDS Rep. 2024 Oct;21(5):264-281. doi: 10.1007/s11904-024-00705-0. Epub 2024 Aug 9.
3
HIV Pre-exposure prophylaxis (PrEP) modalities and service delivery preferences among black cisgender emerging and older adult women in Baltimore, Maryland.马里兰州巴尔的摩市黑人顺性别年轻及老年女性中HIV暴露前预防（PrEP）模式及服务提供偏好
BMC Public Health. 2025 Jul 29;25(1):2579. doi: 10.1186/s12889-025-23775-0.
4
Exploring pre-exposure prophylaxis (PrEP) modality preferences among black cisgender women attending family planning clinics in Chicago via a cross-sectional mixed-methods study.通过一项横断面混合方法研究，探索芝加哥计划生育诊所中黑人顺性别女性对暴露前预防（PrEP）方式的偏好。
BMJ Public Health. 2025 Jan 19;3(1):e000809. doi: 10.1136/bmjph-2023-000809. eCollection 2025 Jan.
5
HIV Pre-exposure prophylaxis (PrEP) Modalities and Service Delivery Preferences Among Black Cisgender Emerging and Older Adult Women in Baltimore, Maryland.马里兰州巴尔的摩市黑人顺性别年轻及老年女性中HIV暴露前预防（PrEP）模式及服务提供偏好
Res Sq. 2024 Nov 13:rs.3.rs-5112395. doi: 10.21203/rs.3.rs-5112395/v1.
6
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.长效卡替拉韦与每日口服替诺福韦酯富马酸二吡呋酯/恩曲他滨相比预防无对照研究 1 年后与男性发生性行为的顺性别男性和跨性别女性感染 HIV 的疗效和安全性：HPTN 083 随机对照 2b 期和 3 期试验的二次分析。
Lancet HIV. 2023 Dec;10(12):e767-e778. doi: 10.1016/S2352-3018(23)00261-8. Epub 2023 Nov 9.
7
Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment.非洲年轻女性对艾滋病病毒暴露前预防制剂及给药方式的偏好：一项离散选择实验的结果
J Int AIDS Soc. 2025 Feb;28(2):e26422. doi: 10.1002/jia2.26422.
8
Interrogating perceived relevance and feasibility of HIV pre-exposure prophylaxis: A novel model of PrEP acceptability among cisgender women who inject drugs.探讨艾滋病病毒暴露前预防的感知相关性和可行性：注射毒品的顺性别女性中暴露前预防可接受性的新模型。
SSM Qual Res Health. 2023 Dec;4. doi: 10.1016/j.ssmqr.2023.100337. Epub 2023 Sep 14.
9
Development of a Clinic-Based, Sociostructural Intervention to Improve the Provision of Pre-Exposure Prophylaxis for Cisgender Women: Formative Study Using the Assessment, Decision, Adaptation, Production, Topical Experts, Integration, Training, and Testing (ADAPT-ITT) Framework.基于诊所的社会结构干预措施的开发，以改善为顺性别女性提供暴露前预防：使用评估、决策、适应、生产、主题专家、整合、培训和测试（ADAPT-ITT）框架的形成性研究。
JMIR Form Res. 2025 Aug 6;9:e75922. doi: 10.2196/75922.
10
Mapping Implementation Strategies to Address Barriers to Pre-Exposure Prophylaxis Use Among Women Through POWER Up (Pre-Exposure Prophylaxis Optimization Among Women to Enhance Retention and Uptake): Content Analysis.通过 POWER Up（女性中使用暴露前预防措施的优化以增强保留和接受度）来针对女性使用暴露前预防措施的障碍制定实施策略：内容分析。
JMIR Form Res. 2024 Nov 15;8:e59800. doi: 10.2196/59800.

本文引用的文献

1
Active-Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo.采用虚拟安慰剂的HIV预防试验的活性对照试验设计
Stat Med. 2025 Mar 15;44(6):e70022. doi: 10.1002/sim.70022.
2
Event-driven PrEP beyond cisgender men who have sex with men.针对男男性行为者以外的顺性别者的事件驱动型暴露前预防
Lancet HIV. 2025 Feb;12(2):e143-e153. doi: 10.1016/S2352-3018(24)00300-X. Epub 2025 Jan 6.
3
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.双年度利纳卡帕韦或每日 F/TAF 用于预防 cisgender 女性中的 HIV。
N Engl J Med. 2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. Epub 2024 Jul 24.
4
Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women.转变对顺性别女性暴露前预防依从性咨询的叙述方式。
JAMA. 2024 Mar 19;331(11):912-914. doi: 10.1001/jama.2024.0432.
5
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.恩曲他滨和替诺福韦酯二甲苯磺酸盐在顺性别女性中的 HIV 暴露前预防。
JAMA. 2024 Mar 19;331(11):930-937. doi: 10.1001/jama.2024.0464.
6
Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.基于模型的预测 cisgender 女性中保护性 HIV 暴露前预防药物依从性水平。
Nat Med. 2023 Nov;29(11):2753-2762. doi: 10.1038/s41591-023-02615-x. Epub 2023 Nov 13.
7
Person-centered HIV PrEP for cisgender women.针对顺性别女性的以患者为中心的HIV暴露前预防
Nat Med. 2023 Nov;29(11):2707-2708. doi: 10.1038/s41591-023-02618-8.
8
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.部分依从性的顺性别女性中口服暴露前预防 HIV 效果的估计。
Nat Med. 2023 Nov;29(11):2748-2752. doi: 10.1038/s41591-023-02564-5. Epub 2023 Oct 5.
9
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.更新口服恩曲他滨/替诺福韦二吡呋酯用于顺性别女性人类免疫缺陷病毒暴露前预防的依从性-反应。
Clin Infect Dis. 2023 May 24;76(10):1850-1853. doi: 10.1093/cid/ciad021.
10
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.利用恩曲他滨和替诺福韦酯的依从-疗效关系来计算背景 HIV 发病率：一项随机对照试验的二次分析。
J Int AIDS Soc. 2021 May;24(5):e25744. doi: 10.1002/jia2.25744.